Brief: Protara Therapeutics Announces Dosing Of First Patient In Phase 3 Registrational Thrive-3 Trial
07/01/2026 14:07
Jan 7 (Reuters) - Protara Therapeutics Inc TARA.O: PROTARA THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 REGISTRATIONAL THRIVE-3 TRIAL OF IV CHOLINE CHLORIDE IN PATIENTS ON LONG-TERM PARENTERAL SUPPORT Source text: ID:nGNX6nz8yG Further company coverage: TARA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protara Therapeutics
See all newsProtara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses